Literature DB >> 19945059

Genomic variation and neurohormonal intervention in heart failure.

Dennis M McNamara1.   

Abstract

Neurohormonal activation is an important driver of heart-failure progression, and all pharmacologic interventions that improve heart-failure survival inhibit this systemic response to myocardial injury. Adrenergic stimulation of beta(1) receptors in the kidney results in the release of plasma renin, the conversion of peptide precursors to angiotensin II (a2), and ultimately the production of aldosterone. beta(1)-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and aldosterone receptor antagonists all act by inhibiting the activity of critical protein of this core pathway: the beta(1) receptor, ACE, the a2 receptor, and aldosterone synthase. Investigation of the pharmacogenetic interactions of the ACE D/I polymorphism and heart-failure therapy demonstrates the power of genomics to target therapeutics. This review explores how genetic variation in genes involved in neurohormonal activation influences heart-failure outcomes and the impact of pharmacotherapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19945059      PMCID： PMC3421049          DOI： 10.1016/j.hfc.2009.08.004

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN： 1551-7136            Impact factor:   3.179


  33 in total

1.  The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers.

Authors:  David C Ishizawar; Karen M Janosko; Jeffrey J Teuteberg; Linda M Cadaret; Michael A Mathier; Dennis M McNamara
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

2.  beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.

Authors:  D J Campbell; A Aggarwal; M Esler; D Kaye
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

3.  Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.

Authors:  M Cicoira; L Zanolla; A Rossi; G Golia; L Franceschini; G Cabrini; A Bonizzato; M Graziani; S D Anker; A J Coats; P Zardini
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

4.  Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction.

Authors:  Barry R Palmer; Anna P Pilbrow; Tim G Yandle; Chris M Frampton; A Mark Richards; M Gary Nicholls; Vicky A Cameron
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

5.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Authors:  M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

6.  Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.

Authors:  L Kurland; H Melhus; J Karlsson; T Kahan; K Malmqvist; K P Ohman; F Nyström; A Hägg; L Lind
Journal:  J Hypertens       Date:  2001-10       Impact factor: 4.844

7.  Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.

Authors:  M Tesauro; W C Thompson; P Rogliani; L Qi; P P Chaudhary; J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy.

Authors:  Armindo D Tiago; Danelle Badenhorst; Daniel Skudicky; Angela J Woodiwiss; Geoffrey P Candy; Richard Brooksbank; Karen Sliwa; Pinhas Sareli; Gavin R Norton
Journal:  Cardiovasc Res       Date:  2002-06       Impact factor: 10.787

9.  Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.

Authors:  Vibha Bhatnagar; Daniel T O'Connor; Nicholas J Schork; Rany M Salem; Caroline M Nievergelt; Brinda K Rana; Douglas W Smith; George L Bakris; John P Middleton; Keith C Norris; Jackson T Wright; Deanna Cheek; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  J Hypertens       Date:  2007-10       Impact factor: 4.844

10.  Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure.

Authors:  Andreia Biolo; Tania Chao; Toni-Ann S Duhaney; Eugene Kotlyar; Donald Allensworth-Davies; Joseph Loscalzo; Flora Sam
Journal:  Am J Cardiol       Date:  2007-06-04       Impact factor: 2.778
View more
  3 in total

1.  The power of Pasteur's quadrant: cardiovascular disease at the turn of the century.

Authors:  Richard I Levin; Glenn I Fishman
Journal:  FASEB J       Date:  2011-06       Impact factor: 5.191

2.  Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism.

Authors:  Kathryn M Meurs; Joshua A Stern; Clarke E Atkins; Darcy Adin; Brent Aona; Julia Condit; Teresa DeFrancesco; Yamir Reina-Doreste; Bruce W Keene; Sandy Tou; Jessica Ward; Kathleen Woodruff
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Oct-Dec       Impact factor: 1.636

3.  Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling.

Authors:  Felipe Neves de Albuquerque; Andréa Araujo Brandão; Dayse Aparecida da Silva; Ricardo Mourilhe-Rocha; Gustavo Salgado Duque; Alyne Freitas Pereira Gondar; Luiza Maceira de Almeida Neves; Marcelo Imbroinise Bittencourt; Roberto Pozzan; Denilson Campos de Albuquerque
Journal:  Arq Bras Cardiol       Date:  2013-11-26       Impact factor: 2.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.